Why the study?
Does nesiritide improve hemodynamics and dyspnea in patients with acute decompensated congestive heart failure and renal insufficiency?
Population
489 patients with acute decompensated congestive heart failure from the VMAC trial database, including a…
Comparison
Nesiritide (B-type natriuretic peptide) infusion vs Placebo added to standard therapies, and…
Design
RCT, randomized
Follow-up
24 h
Key result
Nesiritide significantly reduced pulmonary capillary wedge pressure and improved dyspnea at 24 hours in 83% of acute heart failure patients with renal insufficiency.
Authors
Loading...
Supports nesiritide in acute HF with renal insufficiency; extends RCT evidence to this high-risk subgroup.
RCT (n=489)
Yes
Does nesiritide improve hemodynamics and dyspnea in patients with acute decompensated congestive heart failure and renal insufficiency?
Nesiritide safely improves hemodynamics and dyspnea in patients with acute decompensated heart failure and renal insufficiency without worsening renal function.
Javed Butler (2004) conducted an RCT in Acute decompensated congestive heart failure (n=489). Nesiritide vs. Placebo and Nitroglycerin was evaluated on Pulmonary capillary wedge pressure (PCWP) at 3 hours. Nesiritide significantly reduced pulmonary capillary wedge pressure and improved dyspnea at 24 hours in 83% of acute heart failure patients with renal insufficiency.